4D Molecular Therapeutics Inc
FDMT5.110USD
-1.310-20.41%
交易中 （美东）报价延迟15分钟
236.72M总市值
亏损市盈率 TTM
关于 4D Molecular Therapeutics Inc 公司
4D Molecular Therapeutics, Inc. 是一家临床阶段的基因药物公司，专注于充分发挥基因药物在治疗眼科和肺病方面的潜力。该公司拥有一系列基因药物候选产品，其中五种候选产品正在七种患者群体中进行临床试验：4D-150 用于治疗湿性老年性黄斑变性 (wet AMD) 和糖尿病性黄斑水肿 (DME)，4D-710 用于治疗囊性纤维化肺病（调节剂不合格和合格人群），4D-310 用于治疗法布里病心肌病，4D-125 用于治疗 X 连锁视网膜色素变性 (XLRP)，4D-110 用于治疗脉络膜缺失。此外，该公司还有两种处于临床前开发阶段的产品候选药物：用于治疗地图样萎缩（GA）的4D-175和用于治疗α-1抗胰蛋白酶缺乏肺病的4D-725。
公司简介
公司代码FDMT
公司名称4D Molecular Therapeutics Inc
上市日期Dec 11, 2020
CEODr. David Kirn, M.D.
员工数量227
证券类型Ordinary Share
年结日Dec 11
公司地址5858 Horton Street #455
城市EMERYVILLE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94608
电话15105052680
网址https://4dmoleculartherapeutics.com/
公司代码FDMT
上市日期Dec 11, 2020
CEODr. David Kirn, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Robert (Bob) Kim, M.D.
Dr. Robert (Bob) Kim, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
14.00K
0.00%
Netherlands
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
9.85%
BVF Partners L.P.
9.85%
Goldman Sachs & Company, Inc.
8.09%
BlackRock Institutional Trust Company, N.A.
7.63%
The Vanguard Group, Inc.
5.95%
Other
58.64%
持股股东
持股股东
占比
RA Capital Management, LP
9.85%
BVF Partners L.P.
9.85%
Goldman Sachs & Company, Inc.
8.09%
BlackRock Institutional Trust Company, N.A.
7.63%
The Vanguard Group, Inc.
5.95%
Other
58.64%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
23.29%
Investment Advisor
21.67%
Hedge Fund
17.81%
Venture Capital
16.25%
Research Firm
14.94%
Individual Investor
3.88%
Sovereign Wealth Fund
1.08%
Pension Fund
1.01%
Bank and Trust
0.10%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
351
46.53M
100.45%
-12.51M
2025Q1
358
46.38M
99.71%
-13.16M
2024Q4
357
49.60M
107.13%
-13.93M
2024Q3
350
60.77M
117.85%
-4.39M
2024Q2
340
60.30M
117.01%
-2.54M
2024Q1
324
59.47M
116.84%
+10.27M
2023Q4
284
45.54M
106.82%
-1.53M
2023Q3
275
45.63M
108.12%
-4.94M
2023Q2
263
44.82M
109.79%
-393.70K
2023Q1
254
34.42M
103.72%
-2.13M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
4.56M
9.85%
--
--
Mar 31, 2025
BVF Partners L.P.
4.56M
9.85%
+1.89M
+70.79%
Mar 31, 2025
Goldman Sachs & Company, Inc.
3.75M
8.09%
-81.59K
-2.13%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.53M
7.63%
-321.37K
-8.34%
Mar 31, 2025
The Vanguard Group, Inc.
2.76M
5.95%
-97.19K
-3.40%
Mar 31, 2025
Novo Holdings A/S
1.95M
4.21%
+450.00K
+30.00%
Mar 31, 2025
Janus Henderson Investors
1.89M
4.08%
-360.31K
-16.00%
Mar 31, 2025
Kirn (David)
1.66M
3.58%
-360.00
-0.02%
Apr 24, 2025
Millennium Management LLC
1.63M
3.53%
+213.26K
+15.01%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.29M
2.78%
-316.21K
-19.71%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Federated Hermes MDT Small Cap Core ETF
0.32%
Harbor Human Capital Factor US Small Cap ETF
0.08%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
iShares Health Innovation Active ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
查看更多
Federated Hermes MDT Small Cap Core ETF
占比0.32%
Harbor Human Capital Factor US Small Cap ETF
占比0.08%
iShares Micro-Cap ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
Invesco Nasdaq Biotechnology ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
iShares Health Innovation Active ETF
占比0.02%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
